A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2015
At a glance
- Drugs Daclatasvir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 06 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jan 2011 Actual end date (Sep 2010 ) added as reported by ClinicalTrials.gov.
- 02 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.